Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
The present disclosure describes furo- and thieno-pyridine carboxamide compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
1. The compound of Formula (II-6):
or a pharmaceutically acceptable salt thereof, wherein:
n RA is 0;
Cy B is a 3-aminopiperidin-1-yl, wherein said piperidinyl is optionally substituted with 1, 2, 3, or 4 R B ;
each R B is independently selected from halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, CN, OR a2 and NR c2 R d2 ;
R 5 is H, halogen, or C 1-6 alkyl;
R 6 is H, halogen, R 6A , C 1-6 haloalkyl, CN, or OR a4 ;
R 6A is unsubstituted phenyl or phenyl 2,6-disubstituted with substituents independently selected from C 1-6 alkyl, halogen, CN and OR a4 ;
R 7 is H, halogen, C 1-6 alkyl, C 1-6 haloalkyl or O(C 1-6 alkyl);
R a2 , R c2 and R d2 are each independently selected from H, C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl; and
R a4 is H or C 1-6 alkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the configuration of the carbon atom at the 3-position of the piperidin-1-yl ring forming Cy B is (S).
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the configuration of the carbon atom at the 3-position of the piperidin-1-yl ring forming Cy B is (R).
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy B is a group selected from groups of the following Formulae (B-101) to (B-107):
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy B is a group selected from groups of the following Formulae (B-115) to (B-121):
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Cy B is a group of Formula (B-3a):
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R B is independently selected from methyl, ethyl, cyclopropyl, CF 3 , OH and NH 2 .
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H, Cl or methyl.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is H.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is R 6A .
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is H, Cl, methyl, ethyl, CF 3 , OMe, OEt, On-Pr, or Oi-Pr.
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is H.
14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R a2 , R c2 , and R d2 is independently selected from H and C 1-6 alkyl.
15. The compound of claim 1 , wherein the compound is 2-amino-N-{4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]pyridin-3-yl}-6-(2,6-difluorophenyl)furo[3,2-b]pyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 , wherein the compound is 2-amino-N-{4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]pyridin-3-yl}-6-(2,6-difluorophenyl)furo[3,2-b]pyridine-3-carboxamide.
17. A composition comprising a compound of claim 15 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
18. A composition comprising a compound of claim 16 , and at least one pharmaceutically acceptable carrier.